Effect of sodium-glucose cotransporter-2 inhibitors on circadian blood pressure rhythm in patients with type 2 diabetes mellitus
Abstract
Introduction: The aim of this study was to investigate the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on circadian blood pressure rhythm in normotensive patients diagnosed with
type 2 diabetes mellitus (DM) who were not on antihypertensives.
Methods: The study included normotensive patients with type 2
DM who were initiated on SGLT2 inhibitors (empagliflozin, n=31;
dapagliflozin, n=36) in addition to an antihyperglycemic agent.
Results: Systolic blood pressure (SBP) and diastolic blood pressure
(DBP) changed from a nondipper to a dipper pattern after treatment in
22.4% (n=15) and 25.4% (n=17) of the patients, respectively. Both SBP
and DBP changed from a nondipper to a dipper pattern after treatment in
17.9% (n=12) of all patients. This change in circadian blood pressure was
not significantly different for the dapagliflozin and empagliflozin groups
(p>0.05). Fasting blood sugar and HbA1c levels significantly decreased in
both groups after SGLT2 inhibitor treatment (p<0.001). Serum creatinine
and spot urine microalbumin levels and the microalbumin/creatinine ratio
decreased significantly in both groups (p<0.05). The posttreatment decrease in spot urine protein and creatinine levels was significantly higher
in the dapagliflozin group compared to the empagliflozin group (p<0.05).
Conclusion: The circadian blood pressure pattern changed from a dipper to a nondipper pattern in normotensive type 2 DM patients after they used SGLT2 inhibitors.
Details
| Primary Language | English |
|---|---|
| Subjects | Traditional, Complementary and Integrative Medicine (Other) |
| Journal Section | Research Articles |
| Authors | |
| Publication Date | March 28, 2023 |
| Published in Issue | Year 2023 |